Abstract
Infection is a common complication of cystic fibrosis (CF) airways disease. Current treatment approaches include early intervention with the intent to eradicate pathogens in the hope of delaying development of chronic infection and chronic use of aerosolized antibiotics to suppress infection. The use of molecules that help restore CFTR function, modulate pulmonary inflammation, or improve pulmonary clearance, may also influence the microbial communities in the airways. As the pipeline of these new entities continues to expand, it is important to define when key pathogens are eradicated from the lungs of CF patients and equally important, when new pathogens might emerge as a result of these novel therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 1-23 |
| Journal | Journal of Clinical Microbiology |
| Early online date | 06 Jun 2018 |
| DOIs | |
| Publication status | Early online date - 06 Jun 2018 |
| Externally published | Yes |
Fingerprint
Cite this
}
Pathogen eradication” and “Emerging pathogens”: Difficult definitions in cystic fibrosis. / Gilligan, Peter H; Downey, Damian G; Elborn, J Stuart; Flume, Patrick A; Funk, Sebastian; Gilpin, Deirdre; Kidd, Timothy J; McCaughan, John; Millar, B Cherie; Murphy, Philip G; Rendall, Jacqueline C; Tunney, Michael M; Moore, John E.
In: Journal of Clinical Microbiology, 06.06.2018, p. 1-23.Research output: Contribution to journal › Article
TY - JOUR
T1 - Pathogen eradication” and “Emerging pathogens”: Difficult definitions in cystic fibrosis
AU - Gilligan, Peter H
AU - Downey, Damian G
AU - Elborn, J Stuart
AU - Flume, Patrick A
AU - Funk, Sebastian
AU - Gilpin, Deirdre
AU - Kidd, Timothy J
AU - McCaughan, John
AU - Millar, B Cherie
AU - Murphy, Philip G
AU - Rendall, Jacqueline C
AU - Tunney, Michael M
AU - Moore, John E
N1 - Copyright © 2018 American Society for Microbiology.
PY - 2018/6/6
Y1 - 2018/6/6
N2 - Infection is a common complication of cystic fibrosis (CF) airways disease. Current treatment approaches include early intervention with the intent to eradicate pathogens in the hope of delaying development of chronic infection and chronic use of aerosolized antibiotics to suppress infection. The use of molecules that help restore CFTR function, modulate pulmonary inflammation, or improve pulmonary clearance, may also influence the microbial communities in the airways. As the pipeline of these new entities continues to expand, it is important to define when key pathogens are eradicated from the lungs of CF patients and equally important, when new pathogens might emerge as a result of these novel therapies.
AB - Infection is a common complication of cystic fibrosis (CF) airways disease. Current treatment approaches include early intervention with the intent to eradicate pathogens in the hope of delaying development of chronic infection and chronic use of aerosolized antibiotics to suppress infection. The use of molecules that help restore CFTR function, modulate pulmonary inflammation, or improve pulmonary clearance, may also influence the microbial communities in the airways. As the pipeline of these new entities continues to expand, it is important to define when key pathogens are eradicated from the lungs of CF patients and equally important, when new pathogens might emerge as a result of these novel therapies.
U2 - 10.1128/JCM.00193-18
DO - 10.1128/JCM.00193-18
M3 - Article
C2 - 29875191
SP - 1
EP - 23
JO - Journal of Clinical Microbiology
JF - Journal of Clinical Microbiology
SN - 0095-1137
ER -